Research indicates that around fifty percent of resistant melanoma cells exhibit markedly elevated Rho/MRTF pathway activity (Foda and Neubig, 2023), suggesting that this route is integral to the mechanism of drug resistance. The gene discussed is RHO; the disease is melanoma.